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RIP1 is a central mediator of cell death in response
to cell stress but can also mediate cell survival by
activating NF-kB. Here, we show that RIP1 acts as
a switch in EGFR signaling. EGFRvIII is an oncogenic
mutant that does not bind ligand and is coexpressed
with EGFRWT in glioblastoma multiforme (GBM).
EGFRvIII recruits ubiquitin ligases to RIP1, result-
ing in K63-linked ubiquitination of RIP1. RIP1 binds
to TAK1 and NEMO, forming an EGFRvIII-RIP1
signalosome that activates NF-kB. RIP1 is essential
for EGFRvIII-mediated oncogenicity and correlates
with NF-kB activation in GBM. Surprisingly, activa-
tion of EGFRWT with EGF results in a negative
regulation of EGFRvIII, with dissociation of the
EGFRvIII-RIP1 signalosome, loss of RIP1 ubiquitina-
tion and NF-kB activation, and association of RIP1
with FADD and caspase-8. If EGFRWT is overex-
pressed with EGFRvIII, the addition of EGF leads to
a RIP1 kinase-dependent cell death. The EGFRWT-
EGFRvIII-RIP1 interplay may regulate oncogenicity
and vulnerability to targeted treatment in GBM.
INTRODUCTION
The receptor-interacting protein (RIP, RIP1, RIPK1) is widely
expressed and is a member of a kinase family that mediates
cellular responses to inflammation and stress (Festjens et al.,
2007; Meylan and Tschopp, 2005). RIP1 is also an important
mediator of cell death (Weinlich et al., 2011). RIP1 plays a key
role in apoptotic cell death induced by stimuli such as TNF-a,
DNA damage, or cIAP inhibitors (Bertrand et al., 2008; Petersen764 Cell Reports 4, 764–775, August 29, 2013 ª2013 The Authorset al., 2007; Varfolomeev et al., 2007; Vince et al., 2007). In addi-
tion, RIP1 plays a key role in necrotic forms of cell death trig-
gered when caspase activation is blocked (Feoktistova et al.,
2011; Hitomi et al., 2008; Tenev et al., 2011). Necrotic cell death
under these conditions requires the kinase activity of RIP1 and is
inhibited by a specific inhibitor of RIP1 kinase, termed necrosta-
tin-1 (Degterev et al., 2008).
RIP1 is an essential component of signaling platforms involved
in either NF-kB activation or cell death signaling (Bertrand and
Vandenabeele, 2011). For example, RIP1 forms complexes
with IKKg (NEMO), TRADD, and TAK1 to activate NF-kB in
response to stressful stimuli. The core signaling complex
involved in cell death signaling by RIP1 includes RIP1, FADD,
and caspase-8 (Feoktistova et al., 2011; Tenev et al., 2011).
K63-linked ubiquitination may play a key role in determining
the partners RIP1 associates with and in determining whether
RIP1 acts as a prosurvival adaptor protein or participates in
cell death (Bertrand et al., 2008; Declercq et al., 2009; Ea
et al., 2006; O’Donnell et al., 2007, 2012; O’Donnell and Ting,
2012;Wang et al., 2008). The cIAPs and TRAF2 play an important
role as ubiquitin ligases that mediate K63-linked ubiquitination of
RIP1 (Bertrand et al., 2008). cIAP inhibitors/SMAC mimetics
target cIAPs leading to a RIP1-dependent cell death. Thus, sub-
stantial evidence suggests that RIP1 plays a pivotal role in deter-
mining cell survival or death depending on the cellular context.
Aberrant activation of NF-kB is widespread in human cancer
(Karin et al., 2002; Pacifico and Leonardi, 2006), including
GBM (glioblastoma multiforme), and generally promotes survival
of tumor cells. It has been suggested that two major pathways
activate NF-kB in GBM (Bredel et al., 2011). First, EGFR gene
amplification and aberrant EGFR signaling are detected in
40%–50% of GBMs. EGFR signaling is known to activate
NF-kB (Habib et al., 2001; Sun and Carpenter, 1998; Yang
et al., 2012). Second, NF-kB inhibitor a (NFKBIA, which encodes
IkBa) is commonly deleted in non-EGFR-amplified GBMs,
resulting in NF-kB activation (Bredel et al., 2011). A specific and
oncogenic EGFR mutant (EGFR type III [EGFRvIII], de2–7,
DEGFR) can be detected in about one-third of GBMs (Hatanpaa
et al., 2010; Huang et al., 2009). EGFRvIII is generated from a
deletion of exons 2–7 of the EGFR gene, which results in an in-
frame deletion of 267 amino acids from the receptor. EGFRvIII
is unable to bind ligand and thought to signal constitutively.
EGFRvIII is usually coexpressed with EGFR wild-type (WT) in
GBM (Biernat et al., 2004; Ekstrand et al., 1991). The deletion
of exons 2–7 in EGFRvIII occurs in EGFR gene-amplified tumors
(Biernat et al., 2004; Frederick et al., 2000), suggesting that the
genetic abnormalities that lead to overexpression of EGFRWT
and to expression of EGFRvIII coexist in individual tumor cells.
Immunohistochemical studies also suggest that the two recep-
tors are expressed in the same tumor cells, although in some
GBMs, EGFRvIII may be expressed in a more focal distribu-
tion compared to EGFRWT. However, even focally distributed
EGFRvIII is expressed in cells with EGFRWT expression (Biernat
et al., 2004; Nishikawa et al., 2004). A recent study has sug-
gested that EGFRvIII activates NF-kB via mTORC2 (Tanaka
et al., 2011). NF-kBplays an important role in EGFRvIII-mediated
oncogenicity (Bonavia et al., 2012; Tanaka et al., 2011).
We previously showed that RIP1 is commonly expressed at
high levels in GBM and confers a worse prognosis (Park et al.,
2009). In this study, we propose an essential role for RIP1 in
EGFRvIII-mediated NF-kB activation. Silencing RIP1 inhibits
EGFRvIII-mediated NF-kB activation and oncogenicity in an
orthotopic mouse model. Expression of EGFRvIII leads to
recruitment of the ubiquitin ligases, TRAF2 and cIAP2, to RIP1,
and to EGFRvIII resulting in K63-linked ubiquitination of RIP1
and NF-kB activation. EGFRvIII forms a signaling platform that
incorporates RIP1, NEMO, and TAK1. Both EGFRvIII and RIP1
are required for assembly of this signalosome. Importantly, we
show that EGFRvIII-mediated activation of NF-kB is negatively
regulated by coexpressed EGFRWT. Thus, addition of EGF to
cells to activate EGFRWT results in a rapid loss of RIP1 ubiquiti-
nation and loss of its association with EGFRvIII, NEMO, and
TAK1 and a loss of EGFRvIII-mediated NF-kB activation. RIP1
now becomes associated with the death adaptor FADD in an
EGF-dependent manner. When EGFRWT is overexpressed, as
is common in GBM and other human cancers, EGF becomes a
death signal, and this cell death requires the kinase activity of
RIP1. Thus, RIP1, previously implicated in cell stress and inflam-
matory signaling, is also a key life/death switch in a major recep-
tor tyrosine kinase (RTK) signaling system and turns a normally
trophic signal into a death signal. These findings reveal an antag-
onistic interaction between EGFRWT and EGFRvIII and add
a layer of complexity to our understanding of EGFRvIII and
NF-kB activation in GBM.
RESULTS
EGFRvIII Activates NF-kB in Glioma Cell Lines
EGFRvIII is a tumor-specific EGFR mutant not expressed in
normal tissues or in established GBM cell lines. Stable expres-
sion of EGFRvIII in U87MG cells results in activation of NF-kB
(Bonavia et al., 2012; Tanaka et al., 2011). Because EGFRvIII
does not bind ligand, we generated U87MG cell lines condition-ally expressing EGFRvIII in response to tetracycline (Figure 1A)
as a tool to examine regulated EGFRvIII signaling. Two tetracy-
cline-inducible clones were identified and named U1 and U26.
EGFRvIII can be distinguished from EGFRWT on western blots
as a faster migrating band (Figure 1A). Consistent with previous
studies, conditional expression of EGFRvIII in U1 and U26 cells
leads to activation of NF-kB, as determined by phosphorylation
of the p65 subunit of NF-kB (Figures 1A and S1A). We also
confirmed phosphorylation of p65 in U251-vIII cells (Figure 1A).
U251vIII cells conditionally express EGFRvIII in response to
tetracycline (Ramnarain et al., 2006). Additionally, constitutive
EGFRvIII expression in LN229 cells also results in phosphoryla-
tion of phospho-p65 (Figure 1A), demonstrating that EGFRvIII
activates NF-kB in multiple GBM cell lines. Additionally, we
confirmed that EGFRvIII activated the transcriptional activity of
NF-kB by reporter assays in the various cell lines using an
NF-kB luciferase reporter as shown in Figure 1B. All the GBM
cell lines used express endogenous EGFRWT.
In addition, we examined a panel of primary GBM stem-like
cultures grown as neurospheres (NSs) for the presence of
EGFRvIII (Figure 1C). We selected GBM9 NS cultures (GBM9-
NS) that retain substantial expression of EGFRvIII with a low level
of EGFRWT and demonstrate phosphorylation of the p65 subunit
of NF-kB. Importantly, inhibition of EGFR kinase activity by erlo-
tinib addition abolished phosphorylation of p65 in GBM9-NS,
indicating that EGFRvIII is driving NF-kB activation in these cells
(Figure 1D). Erlotinib also blocks NF-kB transcriptional activity in
GBM9-NS (Figure S1B). A dose response for the concentration
of erlotinib required to inhibit EGFR in U1 cells is shown in Fig-
ures S1C and S1D. A second EGFR kinase inhibitor, AG1478,
also blocked EGFR phosphorylation in U1 cells (Figure S1E).
Next, we examined the effect of combined EGFRWT and
EGFRvIII activation by exposing these cells to EGF. Unexpect-
edly, we found that exposure of cells to EGF leads to a complete
loss of EGFRvIII-mediated NF-kB transcriptional activation in
multiple cell lines (Figures 1E and 1F). Adding EGF to U251vIII
cells not exposed to tetracycline (not expressing EGFRvIII) re-
sults in activation of NF-kB (Figure 1E). However, when EGFRvIII
is expressed, ligand-mediated EGFRWT activation not only fails
to activate NF-kB but also abolishes EGFRvIII-mediated NF-kB
activation. Similarly, Figures 1F, S1F, and S1G show that addi-
tion of EGF abolishes EGFRvIII-mediated activation of NF-kB
in U1 cells, U26 cells, and LN229-vIII cells. Electrophoretic
mobility shift assays also demonstrate a loss of EGFRvIII-
mediated NF-kB DNA binding in U1 cells in response to EGF
(Figure S2A). Thus, EGF-mediated activation of EGFRWT results
in a complete reversal of EGFRvIII-mediated NF-kB activation in
multiple cell lines. We examined the ability of EGF to abolish
EGFRvIII-mediated NF-kB activation in U251vIII cells with
silenced EGFRWT. We find that EGF did not abrogate
EGFRvIII-mediated NF-kB activation in EGFRWT-silenced cells
(Figures S2B and S2C). The levels of EGFRvIII expressed in
our experimental system are similar to GBM tumors (Figure 1G).
Next, we examined whether coexpression of both EGFRWT
and EGFRvIII can be detected in the same cells in primary
GBM cultures. Primary NS cultures from both GBM9-NS and
748-NS show coexpression of both EGFRWT and EGFRvIII
(Figure 1C). We generated single-cell suspensions from theseCell Reports 4, 764–775, August 29, 2013 ª2013 The Authors 765
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Figure 1. EGFRvIII Activates NF-kB
(A) Various cell lines with stable expression of
EGFRvIII and endogenous EGFRWT are shown.
U1 cells are U87MG cells conditionally expressing
EGFRvIII in response to tetracycline (tet). U251vIII
cells are U251MG cells conditionally expressing
EGFRvIII in response to tetracycline. LN229-V
cells are transfected with empty vector, whereas
LN229-vIII cells have stable and constitutive
expression of EGFRvIII. Endogenous EGFRWT
can be detected in cells as a slower migrating
band above the EGFRvIII. Expression of EGFRvIII
in various cell lines results in increased phos-
phorylation of the p65 subunit of NF-kB.
(B) Reporter assays show increased transcrip-
tional activity of NF-kB using a luciferase assay.
Conditional or constitutive expression of EGFRvIII
results in increased NF-kB reporter activity (***p <
0.0001, one-way ANOVA). Error bars indicate SD.
RLU, relative luciferase units.
(C) We screened a panel of early-passage primary
GBM cultures grown as NSs for the presence of
EGFRWT and EGFRvIII.
(D) GBM9-NS cells were treated with either erloti-
nib (10 mM) or necrostatin (300 nM) overnight fol-
lowed by western blot for phospho-p65.
(E) A reporter assay shows that the transcriptional
activity of NF-kB in tetracycline-treated U251vIII
is abolished by exposure to EGF. Data were
analyzed by one-way ANOVA followed by New-
man-Keulsmultiple comparison test to validate the
levels of significance between groups and were
statistically significant for all groups (***p < 0.05).
Error bars indicate SD.
(F) Conditional expression of EGFRvIII in U1 cells
results in activation of NF-kB reporter activity,
which is abolished by addition of EGF (50 ng/ml)
(***p < 0.00001, one-way ANOVA). Error bars
indicate SD.
(G) EGFRvIII levels in U1 and U251vIII cells are
comparable to EGFRvIII levels in resected GBM
specimens (GBMs 6 and 10 have high levels of
EGFRvIII).
See also Figures S1, S2, and S3.tumors by limiting dilution and expanded single-cell clonal pop-
ulations. Multiple colonies derived from single cells were exam-
ined for expression of EGFRWT and EGFRvIII by western blot. In
all clonal populations from both tumors, both EGFRvIII and
EGFRWT are coexpressed (Figure S3). Our data thus support
the evidence from previous studies that EGFRvIII is usually coex-
pressed with EGFRWT in the same tumor cells.
A Role for RIP1 in EGFRvIII-Mediated NF-kB Activation
Although it is well known that EGFRvIII activates NF-kB, the
underlying mechanisms are not well understood. On the other
hand, NF-kB activation by cytokines such as TNF-a has been
extensively characterized and involves RIP1. Furthermore, we
previously reported that RIP1 forms a complex with EGFRWT
when both are expressed at high levels, although the signifi-
cance or mechanism of this interaction was not investigated
(Habib et al., 2001). We examined whether EGFRvIII uses
a mechanism similar to TNF-a to activate NF-kB. To examine766 Cell Reports 4, 764–775, August 29, 2013 ª2013 The Authorsa possible role for RIP1 in EGFRvIII signaling, we silenced
RIP1 in U1 cells and U251-vIII cells. Silencing RIP1 inhibits
EGFRvIII-induced NF-kB reporter activity (Figures 2A, 2B, S4A,
and S4B). EGFRvIII-mediated NF-kB activation is abolished by
necrostatin-1, a specific inhibitor of RIP1 kinase (Figures 2C,
1D, and S4C). Thus, both necrostatin-1 and erlotinib inhibit
EGFRvIII-mediated NF-kB activation. These findings suggest
that RIP1 is required for EGFRvIII-mediated NF-kB activation.
A dose response for the concentration of necrostatin-1 required
to inhibit the RIP1 activity in U1 cells was determined by
EGFRvIII-driven phosphorylation of phospho-p65 (Figures S4D
and S4E). RIP1 knockdown by siRNA also inhibits phosphoryla-
tion of p65 (Figure S4F).
Silencing RIP1 Inhibits EGFRvIII-Mediated Oncogenicity
Next, we examined the biological consequences of silencing
RIP1 in EGFRvIII-expressing cells. We used shRNA to stably
silence RIP1 in U1 cells using lentiviral shRNA directed against
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Figure 2. RIP1 Is Essential for EGFRvIII-
Mediated NF-kB Activation and Oncoge-
nicity
(A) RIP1 is essential for EGFRvIII-mediated acti-
vation of NF-kB transcriptional activity in U1 cells.
siRNA-mediated knockdown of RIP1 blocks the
ability of EGFRvIII to activate NF-kB. Addition of
tetracycline results in expression of EGFRvIII in
both RIP1-silenced and control (scrambled) siRNA
control, but NF-kB is activated only in control
siRNA cells (**p = 0.0013, one-way ANOVA). Error
bars indicate SD.
(B) Silencing of RIP1 is shown by western blot.
(C) EGFRvIII-mediated transcriptional activity of
NF-kB is blocked by necrostatin-1 in U1 cells
(*p = 0.017). Error bars indicate SD.
(D) Stable silencing of RIP1 in U1 cells using RIP1
shRNA is presented. Two independent clones with
efficient silencing of RIP1 L11 and S1 are shown
along with RIP1 levels in control scrambled shRNA
(C)-expressing cells.
(E) Demonstration of doxycycline (doxy) pene-
trating into the intracranial tumors to induce
expression of EGFRvIII. Protein lysates were made
from U1-derived intracranial tumors in mice fol-
lowed by western blot with EGFR. Mice 312 and
314 were exposed to doxycycline in drinking water
and food and show expression of both EGFRvIII
and EGFRWT, whereas 311 and 313 were not
exposed to doxycycline and demonstrate
expression of endogenous EGFRWT only.
(F) H&E sections from a representative brain
section from the control shRNA group shows the
presence of brain tumor, whereas the brain section
from the L11 mouse is free of tumor.
(G) Expression of EGFRvIII and RIP1 in tumors
from two mice from the control shRNA group is
presented. Lysates were prepared directly from
tumor tissue followed by western blot.
(H) Kaplan-Meier survival analysis of RIP1-
silenced cells (L11) compared to control shRNA
expression implanted intracranially in mice (n = 8)
is shown. The log rank test was significant (c2(1) =
15.47; p < 0.0001). All mice were exposed to
doxycycline in food and water.
See also Figures S4 and S5.RIP1 or control shRNA followed by puromycin selection. Stable
clones with silenced RIP1 were identified (Figure 2D). We found
that silencing RIP1 resulted in significantly decreased numbers
of cells in culture compared to controls (Figures S5A–S5C).
Next, we tested U1 RIP-silenced cells for growth in an orthotopic
xenograft model of GBM in athymic nude mice. We first
confirmed that EGFRvIII was conditionally expressed in U1 (con-
trol shRNA) cells in intracranial tumors in animals exposed to
doxycycline in drinking water and feed (Figure 2E). Next, we in-
jected cells with silenced RIP1 or control shRNA intracranially
into groups of nude mice. Animals were sacrificed at the onset
of neurological symptoms or after 8 months. Kaplan-Meier sur-
vival analyses were computed to compare the two groups on
time until the appearance of neurological symptoms (the event),
where time was defined as number of days elapsed from injec-
tion to symptom appearance. The median number of days until
the event for the shRIP1-L11 group was 240 days (100%censored data), as opposed to 57 days for the control shRNA
group (Figure 2H). The log rank test was significant (c2(1) =
15.47; p < 0.0001), indicating that shRIP-1-L11 mice remained
symptom-free for a significantly longer period of time than the
control mice. Surprisingly, no animals injected with the shRIP1-
silenced cells formed tumors, whereas all of the animals
with shControl cells formed tumors as shown in Figures 2F–
2H. Both RIP1 and EGFRvIII can be detected in tumors from
U1control shRNA mice (Figure 2G). This experiment suggests
that RIP1 is required for EGFRvIII-mediated oncogenicity.
EGFRvIII Recruits the Ubiquitin Ligases c-IAP1, c-IAP2,
and TRAF2 to RIP1, Resulting in K-63-Linked
Polyubiquitination of RIP1
The ubiquitin ligases involved in K63-linked ubiquitination of
RIP1 have been identified as c-IAP1, c-IAP2, and TRAF2.
Thus, we tested whether conditional EGFRvIII expression leadsCell Reports 4, 764–775, August 29, 2013 ª2013 The Authors 767
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Figure 3. EGFRvIII Recruits Ubiquitin
Ligases to RIP1 Resulting in K63-Linked
Ubiquitination of RIP1
(A) U1 cells were exposed to tetracycline to ex-
press EGFRvIII, followed by immunoprecipitation
(IP) with cIAP2 antibodies and western blot with
EGFR and RIP1.
(B and C) U1 cells were exposed to tetracycline to
express EGFRvIII, followed by immunoprecipita-
tion with TRAF2 or cIAP-1 antibodies and western
blot with EGFR and RIP1.
(D)–(F) The same result is shown in U251vIII cells.
(G) U1 cells were exposed to tetracycline, with or
without EGF (50 ng/ml) as indicated, followed by
IP with RIP1 and western blot with K63-specific
ubiquitin antibodies or RIP1 antibodies. An
increased K63-linked ubiquitination of RIP1 is de-
tected in tetracycline-treated cells that decreases
following exposure to EGF for 1 hr.
(H) The same results are shown in a second
U87MG clone conditionally expressing EGFRvIII
(U26).
See also Figure S5.to increased recruitment of ubiquitin ligases to RIP1. Figures
3A–3C show that expression of EGFRvIII in U1 cells results in
increased association of cIAP2 and TRAF2 with RIP1. cIAP1 is
associated with RIP1 in these cells, but the cIAP1-RIP1 asso-
ciation does not increase with EGFRvIII expression. We also
detected an increased recruitment of c-IAP1, cIAP2, and
TRAF2 to EGFRvIII. As is discussed below, RIP1 is also recruited
to EGFRvIII, suggesting that RIP1 ubiquitination may occur in
EGFRvIII-associated complexes. A similar result is detected in
U251vIII cells (Figures 3D–3F). Expression of EGFRvIII results
in increased K63-linked ubiquitination of RIP1 in U1 cells (Fig-
ure 3G). Importantly, the K63-linked ubiquitination of RIP1 is
lost when EGF is added to cells, consistent with the loss of
EGFRvIII-mediated NF-kB activaton. Similar results were found
in U26 cells and U251vIII cells (Figures 3H and S5D). In U251
cells, RIP1 appears to be constitutively K63-linked ubiquitinated,768 Cell Reports 4, 764–775, August 29, 2013 ª2013 The Authorsas has also been reported for other can-
cer cell types (Feoktistova et al., 2011).
Addition of EGF results in a loss of
K63-linked RIP1 ubiquitination, although
this is delayed compared to U1 cells
(Figure S5D).
Formation of an EGFRvIII-RIP1
Signaling Platform
RIP1 associates with EGFRvIII in U1 and
U251vIII cells. Thus, when we immuno-
precipitate with EGFR antibodies and
perform western blot analysis with RIP1,
the RIP1-EGFRvIII association is detect-
able only in cells exposed to tetracycline.
Interestingly, the RIP1-EGFRvIII associa-
tion is rapidly lost when EGF is added
(Figure 4A). No significant association of
RIP1 with EGFRWT is detected with orwithout ligand. IKKg (NEMO) is an important partner for RIP1 in
NF-kB activation. We find that NEMO forms a complex with
RIP1 that is dependent on EGFRvIII, as demonstrated by immu-
noprecipitation with NEMO antibodies followed by western
blotting with RIP1. These data suggest that EGFRvIII induces
formation of an NF-kB signaling complex. Remarkably, the
RIP1-NEMO complex dissociates when EGF is added (Fig-
ure 4B). Furthermore, NEMOalso binds to the EGFRvIII, suggest-
ing the formation of a RIP1-NEMO-containing signaling complex
associated with EGFRvIII. TAK1 is another important component
of the NF-kB activation network and phosphorylates the IKK
complex, an event that culminates in NF-kB activation. TAK1
also forms a complex with RIP1 when EGFRvIII is expressed
and dissociates from RIP1 and EGFRvIII when EGF is added to
cells (Figure 4C). Exposure of GBM9-NS cells to an EGFR kinase
inhibitor, erlotinib, blocks the EGFRvIII-RIP1 association, as
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Figure 4. Formation of an EGFRvIII-Associated Signaling Platform
(A) Expression of EGFRvIII in tetracycline-treated U1 cells (left panel) or U251vIII cells (right panel) results in association with RIP1. The EGFRvIII-RIP1 association
is abolished by EGF. The experiment was conducted by treating cells to EGF followed by immunoprecipitation with EGFR antibody and western blot with RIP1
antibody. No association with EGFRWT is detected.
(B) Expression of EGFRvIII in tetracycline-treated cells induces association of RIP1 and NEMO and NEMO and EGFRvIII in U1 cells (left panel) and U251vIII cells
(right panel). EGF treatment abolishes the RIP1-NEMO association and the NEMO-EGFRvIII association. Immunoprecipitation was conducted with NEMO
antibodies followed by western blot with RIP1 antibodies.
(C) Expression of EGFRvIII in tetracycline-treated cells induces association of RIP1 and TAK1 and TAK1 and EGFRvIII in U1 cells (left panel) and U251vIII cells
(right panel). EGF treatment abolishes the RIP1-TAK1 association and the TAK1-EGFR association. Immunoprecipitation was conducted with TAK1 antibodies
followed by western blot with RIP1 antibodies. EGF treatment was for 15 min in (A)–(C).
(D) In GBM9-NS cells, the RIP1-EGFRvIII association is diminished by necrostatin-1 and to a lesser degree by erlotinib. Immunoprecipitation was conducted with
EGFR antibodies followed by western blot with RIP1 antibody.
(E) In GBM9-NS cells, the NEMO-EGFR association is decreased by both necrostatin-1 and erlotinib, whereas the NEMO-RIP1 association is decreased by
erlotinib, but not necrostatin-1. Immunoprecipitation was conducted with NEMO antibodies followed by western blot with EGFR or RIP1.
(F) RIP1 was silenced using RIP1 siRNA in U1 (left panel) and U251vIII cells (right panel), followed by immunoprecipitation with NEMO andwestern blot with EGFR
in the presence or absence of tetracycline. The NEMO-EGFRvIII association is lost if RIP1 is silenced.
(G) The EGFRvIII-TAK1 association is unaffected by RIP1 silencing in U1 cells.
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Figure 5. Association of RIP1 with FADD
and Caspase-8
(A) Association of RIP1 with FADD following
EGF exposure in EGFRvIII-expressing U1 cells is
shown. FADDbecomes associatedwith RIP1 after
EGF exposure for 1 hr in tetracycline-treated cells.
Immunoprecipitation was done with FADD anti-
body followed by western blot with RIP1.
(B) Association of RIP1 with FADD following EGF
exposure in U251-vIII cells is presented.
(C) Association of RIP1 and caspase-8 in U1 cells
is shown. RIP1 is associated with caspase-8 even
in the absence of EGFRvIII in these cells.
(D) In U1 cells, there is no increase in the number
of Annexin-positive or PI-positive cells with either
tetracycline or EGF exposure (50 ng/ml for 24 hr).
Error bars indicate SD.
(E) EGFRvIII becomes constitutively tyrosine
phosphorylated in U1 cells following expression.
Addition of EGF results in increased tyrosine
phosphorylation of EGFRWT but has no effect on
EGFRvIII tyrosine phosphorylation.
(F) EGFRvIII and EGFRWT form a complex with
each other that does not appear to be influenced
by EGF. EGFRWT-Myc or EGFRvIII-HA was
transfected in U87MG cells followed by immuno-
precipitation with Myc and western blot with HA
antibody.does necrostatin-1, albeit to a lesser extent (Figure 4D). In these
cells, the NEMO-RIP1 association is not inhibited by erlotinib,
whereas it is inhibited by necrostatin-1, suggesting that RIP1
kinase activity is required (Figure 4E). Association of NEMO
with the EGFRvIII, however, is decreased by both erlotinib and
necrostatin-1 (Figure 4E). Importantly, RIP1 siRNA knockdown
abolishes recruitment of NEMO but not TAK1 to EGFRvIII in U1
and U251-vIII cells (Figures 4F and 4G). RIP1 does not influence
EGFR levels in these cells. These experiments suggest that
expression of EGFRvIII leads to recruitment of RIP1, NEMO,
and TAK1 to EGFRvIII and that EGFRvIII promotes association
of RIP1 with NEMO and TAK1 in this complex.
Formation of a RIP1-FADD Complex in Response to EGF
Although EGFRvIII expression leads to increased association of
NEMO and TAK1 with RIP1, it does not induce the association of
FADD with RIP1. Interestingly, when EGF is added to EGFRvIII-
expressing cells, RIP1 loses its association with NEMO and
TAK1 and forms a second complex with FADD. The FADD-RIP1
association is EGF dependent and can be detected in U1 as770 Cell Reports 4, 764–775, August 29, 2013 ª2013 The Authorswell as U251vIII cells (Figures 5A and
5B).Caspase-8 appears to becomplexed
with RIP1 in U1 cells (Figure 5C). Thus, a
death complex with RIP, FADD, and cas-
pase-8 forms in the presence of EGF.
However, we do not detect cell death
whenEGF is added toU1cells expressing
EGFRvIII (Figure 5D).
EGFRvIII becomes constitutively tyro-
sine phosphorylated and activated uponexpression in cells. Next, we examined whether EGF influenced
EGFRvIII tyrosine phosphorylation in U1 cells. If EGF is added to
EGFRvIII-expressing cells, tyrosine phosphorylation of EGFRvIII
is unaltered (Figure 5E). As has been reported previously by
Luwor et al. (2004), we find that EGFR coimmunoprecipitates
with EGFRvIII, but the association does not appear to be altered
by EGF (Figure 5F).
Increased Expression of EGFRWT Leads to Ligand
and RIP1-Dependent Cell Death
In the experiments described above, we observed that RIP1
becomes associated with FADD in response to EGF, but this
does not result in cell death. These experiments were conducted
in cells with a relatively low level of endogenous EGFRWT. We
examined whether overexpression of EGFRWT would result in
a RIP1-dependent cell death. It should be noted that the EGFR
gene amplification is detected in 40%–50%of GBMs and results
in overexpression of both EGFRWT as well as mutant forms of
EGFR. Thus, EGFRWT is usually expressed at high levels in
tumors cells expressing EGFRvIII. We stably overexpressed
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Figure 6. Ligand-Mediated Activation of
EGFRWT in U1WT Cells Leads to a RIP1-
Dependent Cell Death
(A) U1WT cells were exposed to EGF (50 ng/ml) for
24 hr, and an Annexin-FACS assay was per-
formed. Unstained cells represent viable cells.
Annexin-positive cells are undergoing apoptosis.
PI-positive cells are undergoing necrosis. In
‘‘Control,’’ cells are treatedwith control vehicle (ve;
PBS). In the absence of EGF, there is no cell death.
When EGF is added to tetracycline-treated cells,
the number of viable cells is decreased (p <
0.0009), and there is evidence of both apoptotic
(p < 0.005) and necrotic cell death (p < 0.005).
Double-stained cells (Annexin+PI positive) are also
shown.
(B) Necrostatin-1 (300 nM) inhibits the EGF-
induced cell death, demonstrating the requirement
for RIP1 in EGF-induced cell death. There is an
increase in viable cells (p < 0.009) and a decrease
in apoptotic (p < 0.001) and necrotic cells (p <
0.001). As a control for necrostatin-1, cells were
treated with DMSO in EGF+tet cells. Data were
analyzed by one-way ANOVA followed by New-
man-Keuls multiple comparison test.
(C) siRNA knockdown of RIP1 in U1WT cells
inhibits EGF-induced apoptotic cell death. Cells
were transfected with control (scrambled) or RIP1
siRNA followed by EGF exposure for 24 hr and
FACS analysis to compare Annexin-positive cells.
Exposure to EGF leads to substantial increase in
apoptotic (Annexin-positive) cells in control siRNA
cells. This apoptotic cell death is inhibited in RIP1
siRNA cells (p < 0.0001).
(D) siRNA knockdown of RIP1 in U1WT cells in-
hibits EGF-induced necrotic cell death. Exposure
to EGF (24 hr) leads to substantial increase in
necrotic (PI-positive) cells in control siRNA cells.
This necrotic cell death is inhibited in RIP1 siRNA
cells (p < 0.0001).
(E) Double-stained cells (positive for Annexin and
PI) for the same experiment are shown.
(F) RIP1 and caspase-8 form a complex with FADD
in response to EGF in U1WT cells. Upon addition of
EGF, there is a rapid increased association of RIP1
and caspase-8 with FADD. Cells were exposed to
tetracycline in all lanes to induce expression of
EGFRvIII.
Error bars indicate SD. See also Figures S6
and S7.EGFRWT in U1 that conditionally expresses EGFRvIII in
response to tetracycline (U1WT cells). The level of EGFRWT in
U1WT cells is similar to levels in actual GBM tumors (Figure S5E).
Next, we examinedwhether exposure of U1WTcells to EGF re-
sults in cell death. Expression of EGFRvIII by exposure of cells to
tetracycline induces no cell death. However, if cells are exposed
to EGF for 24 hr, there is a robust cell death that has elements of
both apoptosis and necrosis (Figures 6A and S6A). Importantly,
this cell death is blocked by the use of necrostatin-1, indicating
a requirement for RIP1 kinase activity (Figure 6B). A FACS plot
of original data for Figures 6A and 6B is shown in Figure S7A.
If EGF exposure is continued for 72 hr, the cell death detected
is primarily necrotic and again blocked by necrostatin-1 (Fig-ure S6A). siRNA knockdown of RIP1 also blocks EGF-induced
cell death in U1WT cells, confirming the essential requirement
for RIP1 in EGF-mediated cell death (Figures 6C–6E and S6B).
EGF-induced and RIP1-dependent cell death is also detected
in a second cell line expressing both high levels of EGFRWT
and EGFRvIII (U251vIIIWT cells, Figures S6C and S6D).
We also confirmed a loss of EGFRvIII-induced NF-kB activa-
tion in U1WT cells in response to EGF (Figure S6E). This loss of
NF-kB activation is consistent with the EGF-induced switch to
cell death because NF-kB activation generally promotes cell sur-
vival. Furthermore, treatment of U1WT cells with EGF results in
a rapid formation of a death signaling complex with increased
EGF-dependent association of FADD with RIP1 and caspase-8Cell Reports 4, 764–775, August 29, 2013 ª2013 The Authors 771
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A B Figure 7. RIP1 Expression Correlates with
Activation of NF-kB in GBM
(A) Western blot shows expression of EGFRWT,
EGFRvIII, and phospho-p65 in a panel of 23
GBMs. Lysates were made directly from resected
tumors followed by western blot. EGFRvIII is
expressed in only a subset of GBMs (usually with
EGFRWT), whereas phosphorylation of p65 can
be detected in the majority of GBMs as can RIP1.
(B) RIP1 correlates with phosphorylation of p65 in
GBMs. There was a significant positive correlation
between the expression of RIP1 and pp65 using
Pearson correlation (r = 0.49; p < 0.05).
See also Figure S7.(Figure 6F). Moreover, the complex persists for up to 24 hr
(Figures S6F and S6G).
Expression of EGFR, RIP1, and Phosphorylation of p65
in GBMs
Next, we examined expression of EGFR, RIP1, and phospho-
p65 in tumor lysates made directly from GBM tissue (Figure 7A).
EGFRvIII mRNA levels were also detected by quantitative real-
time PCR (Figure S7B). In this series of 23 GBMs, 30% of tumors
express EGFRvIII. In six out of seven GBMs, EGFRvIII is ex-
pressed in the presence of EGFRWT, whereas EGFRvIII appears
to be expressed without EGFRWT in one tumor. Although phos-
phorylation of p65 can be detected in every tumor that expresses
EGFRvIII, p65 is also phosphorylated in tumors that are not
EGFR amplified, consistent with an additional mechanism(s) of
NF-kB activation in GBM. As previously noted, a major mech-
anism of NF-kB activation in GBMs is deletion of NFKBIA,
detected usually in GBMs that do not have amplified EGFR.
Importantly, RIP1 is expressed widely in GBMs, and the pres-
ence of RIP1 correlates with phosphorylation of p65 in GBM as
shown in Figures 7A and 7B (p < 0.05, Pearson correlation).
Thus, themajor components of the EGFRvIII-RIP1-pp65 network
are detectable in GBM.772 Cell Reports 4, 764–775, August 29, 2013 ª2013 The AuthorsDISCUSSION
RIP1 has emerged as a key mediator
of survival and cell death in the con-
text of cellular stress and inflammatory
signaling. RIP1 has been reported to
play an essential role in activation of
NF-kB in response to TNF-a, TLR3, and
DNA damage. Recent studies have eluci-
dated a key role for RIP1 in both apoptotic
and necrotic forms of cell death. In gen-
eral, the prosurvival actions of RIP1 are
likely to be mediated largely by activation
of NF-kB. Posttranslational modifica-
tions of RIP1, such as K63-linked poly-
ubiquitination, may determine the nature
of RIP1 signaling partners and the biolog-
ical outcome. RTK signaling pathways
are of central importance in cancer. Our
study suggests that RIP1 plays a role asa cell life/death switch in a classical oncogenic RTK signaling
pathway in an interaction between EGFRWT and the oncogenic
EGFR mutant EGFRvIII.
We propose a model for EGFRvIII-mediated activation of
NF-kB that involves recruitment of components of the network
that mediates TNF-a-induced NF-kB activation. First, EGFRvIII
recruits the ubiquitin ligases c-IAP1, c-IAP2, and TRAF2 to
RIP1 and to EGFRvIII, resulting in K63-linked ubiquitination of
RIP1. EGFRvIII forms a signaling complex by recruiting RIP1,
NEMO, and TAK1 to EGFRvIII and also increases the association
of RIP1 with NEMO and TAK1. Importantly, RIP1 is required for
the recruitment of NEMO to EGFRvIII. An unusual feature of
EGFRvIII-mediated NF-kB activation is the requirement for the
kinase activity of RIP1. Previous studies suggested that RIP1
kinase activity is dispensable for NF-kB activation. However, in
a recent study, it was shown that Etoposide-induced NF-kB acti-
vation occurs in two phases and that RIP1 kinase activity is
required for the second phase (Biton and Ashkenazi, 2011).
Our study demonstrates that RIP1 is required for EGFRvIII-
mediated oncogenicity. Stable silencing of RIP1 in U87MG cells
expressing EGFRvIII results in slowed proliferation of cells in cul-
ture and, importantly, abrogates EGFRvIII-mediated tumorige-
nicity in an in vivo orthotopic model. In our experiment, none of
the eight animals inoculated with RIP1-silenced EGFRvIII cells
formed intracranial tumors over an observation period of
8 months, whereas all of the animals with control shRNA formed
intracranial tumors in about 57 days. Presumably, the lack of
EGFRvIII-mediated tumorigenicity results from a loss of the abil-
ity of EGFRvIII to activate NF-kB.
An intriguing observation is the unexpected finding that ligand-
mediated activation of EGFRWT abolishes EGFRvIII-mediated
NF-kB activation using RIP1 as a switch. This is unexpected
because both EGFRWT and EGFRvIII are known to activate
NF-kB, and one would predict a synergistic effect. Synergistic
interactions reported previously include EGFRvIII-mediated
induction of the EGFRWT ligand HB-EGF in an autocrine loop
and paracrine effects of EGFRvIII on EGFRWT via an IL-6-
mediated pathway (Inda et al., 2010; Ramnarain et al., 2006).
EGFRvIII is expressed almost exclusively in tumors with EGFR
gene amplification and EGFRWT overexpression. As discussed,
immunohistochemical studies examiningexpression of EGFRWT
and EGFRvIII and our data support the coexpression of EGFRWT
and EGFRvIII in individual tumor cells. Our current studies show
that ligand-mediated activation of EGFRWT results in a dissocia-
tion of the EGFRvIII-associated signaling complex composed of
RIP1, NEMO, and TAK1 as well as a separation of RIP1 from
NEMO and TAK1. This is associated with loss of K63-linked
RIP1 ubiquitination and a complete loss of NF-kB activation.
We propose that activation of EGFRWT induces conformational
changes in EGFRvIII, leading to a loss of EGFRvIII signalosome,
a hypothesis that will be examined in future studies.
Our study provides evidence that a RIP1 switch operates in
EGFR signaling. First, EGFRvIII forms a physical complex with
RIP1 and associated signaling proteins, recruits ubiquitin ligases
to RIP1 resulting in K63-linked ubiquitination of RIP1 leading
to NF-kB activation via a RIP1-dependent pathway. Ligand-
mediated activation of EGFRWT results in a dissolution of the
EGFRvIII signalosome, leading to a loss of RIP1 association
with key signaling proteins, such as NEMO, TAK1, EGFRvIII,
deubiquitination of RIP1, and a complete loss of NF-kB activa-
tion. Addition of EGF now results in an association of RIP1 with
FADD and caspase-8. Thus, addition of EGF in the presence of
EGFRvIII shifts RIP1 toward a cell death role. Although exposure
to EGF does not result in cell deathwhen cells express a low level
of EGFRWT, when EGFRWT is overexpressed to levels similar to
those detected in actual GBM tumors, EGF becomes a death
signal. This is remarkable because EGF is normally a trophic
factor. This cell death has features of both apoptosis and necro-
sis, and it requires the kinase activity of RIP1. Thus, the addition
of EGF results in unleashing the RIP1 switch all the way from an
EGFRvIII-RIP1-NF-kB oncogenic signal to a RIP1-FADD-cas-
pase-8 cell death signal. Although it is somewhat counterintuitive
that a growth factor receptor would induce cell death, there are
precedents for life/death signaling switches. For example, cas-
pase-8, traditionally viewed as an apoptotic protein, also has a
role in survival (Dillon et al., 2012). Similarly, increased expres-
sion of EGFRWT has previously been implicated in growth
suppression and apoptosis (Armstrong et al., 1994; Gill and
Lazar, 1981).
RIP1 is expressed in most GBMs and is coexpressed with
EGFRvIII in tumors showing evidence of NF-kB activation, sug-gesting that the mechanisms detected in our experimental
system may be operational in GBM. Thus, EGFRvIII-mediated
activation of NF-kB may be a major target for treatment.
Because RIP1 mediates EGFRvIII activation of NF-kB, inhibition
of RIP1 using either chemical inhibition of silencing approaches
could be a potentially important treatment in GBM. In addition,
our data suggest that EGFRWT activation could be amechanism
for activating the cell death function of RIP1 in GBM. Further-
more, the availability of endogenous EGFRWT ligand(s) in the
vicinity of EGFRvIII expressing GBM cells may influence the
oncogenic effects of EGFRvIII by abrogating EGFRvIII-mediated
NF-kB activation and by diverting RIP1 into a cell death pathway
that renders tumor cell populations vulnerable to targeted or
conventional therapy.
EXPERIMENTAL PROCEDURES
Plasmids, Transfection, and Generation of Cell Lines
The GBM cell lines U251MG and U87MG were used to generate cell lines
conditionally expressing EGFRvIII using the T-REx Tet-on system from Invitro-
gen, as we have described previously (Ramnarain et al., 2006). EGFRWT with
an HA tag and EGFRvIII with an HA tag were cloned into PcDNA3.1 (Neo)
vector using standard molecular techniques. Lipofectamine 2000 (Invitrogen)
was used for all transfections. To generate cell lines that express high levels
of EGFRWT constitutively along with conditional expression of EGFRvIII, we
stably transfected EGFRWT into U1 and U251vIII cells followed by selection
in G418. Primary GBM cultures were generated directly from human GBMs.
A papain dissociation system was used to dissociate tumors, and cells were
then cultured in Neurobasal medium supplemented with B27 without vitamin
A, and with EGF (10 ng/ml) and bFGF (10 ng/ml). LN229-EGFRvIII cells have
been described previously (Li et al., 2004). At least three independent experi-
ments were done unless otherwise indicated.
Luciferase Assays
Cells were plated in 48-well dishes followed by transfection along with NF-kB-
LUC plasmid using Lipofectamine. A dual-luciferase reporter assay system
was used according to the instructions of the manufacturer (Promega, Madi-
son). Firefly luciferase activity was measured in a luminometer and normalized
on the basis of Renilla luciferase activity.
RNAi
For transient silencing of EGFR, we used a pool of siRNA sequences directed
against human RIP1 or control (scrambled) siRNA obtained from Dharmacon
or QIAGEN. siRNA was performed according to the manufacturer’s protocol
using Lipofectamine 2000 reagent (Invitrogen). For stable silencing of RIP1,
ready-to-use RIP1 lentiviral particles or control shRNA particles were obtained
from Santa Cruz Biotechnology followed by puromycin selection according to
the manufacturer’s protocol. For stable silencing of EGFRWT, we used two
shRNA sequences directed against exon 3 of EGFRWT (Smith et al., 2005)
or control vector followed by selection in G418.
Antibodies, Reagents, and Western Blotting
Western blot and immunoprecipitation were performed according to standard
protocols. For analysis of RIP1 ubiquitination, we followed a protocol
described previously by Biton and Ashkenazi (2011) and as described in the
Extended Experimental Procedures. Details of antibodies used in this study
are outlined in the Extended Experimental Procedures. necrostatin-1 was
obtained from Tocris Bioscience and used at a concentration of 300 nM (over-
night exposure). Erlotinib and AG-1478 were obtained from Selleck Chemicals
and used at a concentration of 10 mM (overnight). EGF was purchased from
PeproTech and used at a concentration of 50 ng/ml.
Primary Tumors
Frozen tissue specimens of human GBMs were received from the research
tumor bank at UT Southwestern Medical Center according to IRB-approved
protocols. Resected tumors were initially frozen at 80C.Cell Reports 4, 764–775, August 29, 2013 ª2013 The Authors 773
Cell Death/Annexin Assay
Annexin assay was done by using Annexin-V-FLUOS Staining Kit (Roche
Applied Science). Cells were cultured in DMEM (10% FBS and Pen/Strep).
Cells (1 3 106) were plated in 6-well plates and treated with EGF for 24 or
72 hr if indicated. The cells were trypsinized and washed two times with 13
PBS. The cells were incubated for 25 min at room temperature with propidium
iodide (PI) and Annexin-V-FLUOS labeling solution in incubation buffer (sup-
plied by the manufacturer). Annexin and/or PI-positive cells were detected
by flow cytometry.
Orthotopic Implants
For intracerebral stereotactic inoculation, 2 3 105 cells were suspended in
PBS and Matrigel (5 ml) and injected into the right corpus striatum of the brains
of 6- to 8-week-old nude mice using a stereotactic frame (BALB/c nu/nu).
Animals were monitored for neurological signs and sacrificed when neurolog-
ical signs appeared or after 240 days. All animal studies were done under
IACUC-approved protocols.
Statistical Analysis
Error bars represent the mean ±SD of three independent experiments. All data
were analyzed for significance using GraphPad Prism 5.0 software, where
p < 0.05 was considered statistically significant. One-way ANOVA and two-
tail t test were used to compare groups. Survival analysis for mice is described
in the Results. Additional information about Experimental Procedures is pro-
vided in the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2013.07.025.
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